The city of Marietta, Ga., has joined a growing list of unions and local governments to file a lawsuit contending Mallinckrodt (MNK) caused them to spend excessively for a medicine because of its high price. The city also alleges the company used several purportedly inappropriate tactics designed to boost usage.

In their lawsuit, Marietta officials argued the city’s self-funded health plan was forced to spend more than it should have because of the “exorbitant and unconscionable” price charged for Acthar Gel, which is used to treat infantile spasms and relapsing multiple sclerosis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy